ArticleCancer science2004
Frequent promoter methylation and gene silencing of CDH13 in pancreatic cancer.
Article in Cancer science, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 59 citations in OpenAlex.
- Gene-gene interaction analysis identifies a new genetic risk factor for colorectal cancer.Journal of biomedical science · 2015Trial
- Environmental Xenobiotics and Epigenetic Modifications: Implications for Human Health and Disease.Journal of xenobiotics · 2025Review
- Review
- Interactive association between dietary fat and sex on CDH13 cg02263260 methylation.BMC medical genomics · 2021Article
- RETRACTED: lncRNA RMST Enhances DNMT3 Expression through Interaction with HuRMolecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment.International journal of molecular sciences · 2017Review
- HPV16 integration probably contributes to cervical oncogenesis through interrupting tumor suppressor genes and inducing chromosome instability.Journal of experimental & clinical cancer research : CR · 2016Article
- Chromosome 16q genesOncology letters · 2016Article
- Article
- Clinicopathological significance and potential drug target of T-cadherin in NSCLC.Drug design, development and therapy · 2015Article
- SOX15 is a candidate tumor suppressor in pancreatic cancer with a potential role in Wnt/β-catenin signaling.Oncogene · 2014Article
- Prognostic significance of CDH13 hypermethylation and mRNA in NSCLC.OncoTargets and therapy · 2014Article
- DNA-intercalators causing rapid re-expression of methylated and silenced genes in cancer cells.Oncotarget · 2013Article
- Correlation between T-cadherin gene expression and aberrant methylation of T-cadherin promoter in human colon carcinoma cells.Medical oncology (Northwood, London, England) · 2012Article
- Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma.International urology and nephrology · 2012Article
- Advances in biomarker research for pancreatic cancer.Current pharmaceutical design · 2012Review
- Involvement of members of the cadherin superfamily in cancer.Cold Spring Harbor perspectives in biology · 2009Review
- Adiponectin receptors, with special focus on the role of the third receptor, T-cadherin, in vascular disease.Medical molecular morphology · 2007Review
- Intra- and interindividual epigenetic variation in human germ cells.American journal of human genetics · 2006Article
- An adiponectin receptor, T-cadherin, was selectively expressed in intratumoral capillary endothelial cells in hepatocellular carcinoma: possible cross talk between T-cadherin and FGF-2 pathways.Virchows Archiv : an international journal of pathology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has recently been reported that CDH13 expression is silenced by aberrant methylation of the promoter region in several cancers. We examined the methylation status of the CDH13 gene in pancreatic cancer using methylation-specific PCR (MSP), and detected aberrant methylation of CDH13 in all 6 pancreatic cancer cell lines examined. To confirm the status of the CDH13 gene in relation to the methylation pattern, we next examined CDH13 expression in these cell lines using reverse transcription (RT)-PCR. As expected, no CDH13 expression was detected in any of the 6 pancreatic cancer cell lines. Moreover, 5-aza-2'-deoxycytidine (5-aza-dC) treatment of CDH13-methylated cell lines led to restoration of CDH13 expression. Among primary pancreatic cancers, 19 of 33 (58%) cases exhibited CDH13 methylation, while no cases exhibited it in corresponding normal pancreatic tissues. CDH13 methylation was detected even in relatively early pancreatic cancers, such as stage II cancers and cancers less than 2 cm in diameter. Our results suggest that the aberrant methylation of CDH13 occurs frequently in pancreatic cancer, even at a relatively early stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.